The phase 2 NeoTOP study was designed to assess the interest of dual HER2 targeting in the neoadjuvant setting combined with anthracycline-based or anthracycline-free chemotherapy according to TOP2A status in women with operable HER2 + BC. This evidence concerns the gene ERBB2 and breast cancer.